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In the first case, the deletion of the b3 exon could be explained if the deletion took place in the b3 exon itself, or if this exon was included in deletions at the breakpoint site. However, in the second case, only a duplication of the b3 exon could explain this discrepancy. Therefore, in these cases, both duplication and deletion have the same target, that is, b3. We have analyzed the t(9;22) translocation by RT-PCR in 32 patients with CML, and we found the bcr-abl hybrid in 29 of them (91%), 16 of the b3/a2 type and 13 of the b3/a2 type. For these bcr-abl positive patients, we tried to detect the reciprocal translocation abl-bcr, and we found this transcript in 19 patients (65.5%). In most of them, the breakpoints were located between the alternative exons 1b and 1a, giving only transcripts with the 1b alternative exon. Only in three cases where breakpoints took place between exon 1a and exon 2, we found two alternative abl hybrids, 1a-bcr and 1b-bcr.
Although in most of the patients, the junction type in bcrabl was exactly reciprocal to the junction in abl-bcr (79%), we found four cases where neither transcripts correlated one with the other. These included two b2/a2 patients who expressed only the abl-b4 transcript, and two b2/a2 patients with the alternative hybrid 1b-b2 in one of them and three alternative transcripts, 1b-b2, 1b-b3 and 1b-b4, in the other. In this last patient, there is alternative splicing of the abl 1b exon to BCR exons b4 (thus jumping over b2 and b3), b3 or b2. These two cases represent the first evidence of duplication of b2 exon of the BCR gene during the molecular rearrangement that occurs in the t(9;22) translocation. In addition, in one of these cases, the reciprocal abl-bcr hybrid mRNA is able to splice out one or two bcr exons.
It has been postulated that the intron preceding abl exon II contains a large tract of pyrimidines immediately upstream of the splice point, which might be associated with the unique splicing characteristics of this exon. 3 This DNA region could be responsible for the alternative splicing that accounts for the 1b or 1a transcripts of the ABL gene, as well as for the two alternative b3/a2 and b2/a2 transcripts that could sometimes be present in the same CML sample. In those patients with two alternative forms of the hybrid abl-bcr gene (eg 1a-bcr and 1b-bcr), and the patient with three alternative transcripts of the present study, the pyrimidine track could not be responsible for this alternative splicing because it is translocated to the bcr-abl hybrid gene. For this reason, other mechanisms must be involved in the alternative splicing observed in the abl-bcr hybrid gene. In this way, the BCR gene is known to express mRNAs of 4.5 and 6.7 kb, which apparently encode for the same cytoplasmic 160 kDa protein. 4 The process that originates these alternative transcripts could also be implicated in the formation of the alternatives mRNAs of the abl-bcr hybrid gene.
In the aberrant cases, where the translocation has been shown not to be reciprocal, duplications are more frequent than deletions, and always occur in the major region of the BCR gene, 1, 4 suggesting a selection for these exons in both chimeric proteins. These duplications may represent a fortuitous error of the molecular mechanism implicated in the translocation, but could they contribute to a more malignant phenotype?
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